M-TEER for Moderate to Severe FMR in Symptomatic Heart Failure: Comparison of RESHAPE-HF2 Trial Results With Outcomes in MITRA-FR and COAPT

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Bayer AG; AstraZenca; Edwards Lifesciences; Vectorious; CVRx; Medtronic; Boehringer Ingelheim; Vifor; Abbott Vascular
• Grant Support/Research Contract - Vifor; Abbott Vascular